Get the Stockscreener App
1.15
0.00%
0.00
Pre-market:
1.14
-0.01
-0.87%
Soligenix Inc stock is traded at $1.15, with a volume of 93,012.
It is up +0.00% in the last 24 hours and down -6.50% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
See More
Previous Close:
$1.15
Open:
$1.14
24h Volume:
93,012
Relative Volume:
0.43
Market Cap:
$11.85M
Revenue:
$200.00K
Net Income/Loss:
$-11.37M
P/E Ratio:
-0.4171
EPS:
-2.7573
Net Cash Flow:
$-10.27M
1W Performance:
+0.88%
1M Performance:
-6.50%
6M Performance:
-29.45%
1Y Performance:
-41.33%
1-Day Range:
$1.13
$1.15
1-Week Range:
$1.10
$1.16
52-Week Range:
$1.00
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.15 | 11.54M | 200.00K | -11.37M | -10.27M | -2.7573 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Hedge Fund Bets: Can Soligenix Inc be the next market leader2026 Top Decliners & Long-Term Safe Return Strategies - baoquankhu1.vn
Mycosis Fungoides Treatment Market Surges to US$ 3.42 Billion - openPR.com
Aug Chart Watch: What is the next catalyst for Soligenix IncBond Market & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Technical Analysis: Can Soligenix Inc be the next market leader2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn
SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data - TradingView — Track All Markets
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26 - Zacks Small Cap Research
Stock Recap: Is Soligenix Inc a speculative investmentPortfolio Update Report & Reliable Entry Point Alerts - baoquankhu1.vn
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - The Globe and Mail
[EFFECT] SOLIGENIX, INC. SEC Filing - Stock Titan
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - Sahm
Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - NewMediaWire
Soligenix (SNGX) Announces Positive Study Results for HyBryte in CTCL Treatment - GuruFocus
Positive Clinical Results from HyBryte™ Comparative Study Evalua - GuruFocus
HyBryte study shows faster response vs Valchlor in lymphoma trial By Investing.com - Investing.com Canada
HyBryte study shows faster response vs Valchlor in lymphoma trial - Investing.com
Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - TipRanks
Soligenix reports 2025 results, eyes Q2 trial data By Investing.com - Investing.com South Africa
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Soligenix (NASDAQ: SNGX) registers 1,054,688 resale shares from warrants - Stock Titan
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Soligenix (SNGX) 2025 10-K outlines CTCL, psoriasis and vaccine programs - Stock Titan
Buybacks Report: Can Soligenix Inc grow without external funding2026 Volatility Report & Safe Entry Trade Reports - baoquankhu1.vn
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - Bitget
Soligenix reports 2025 results, eyes Q2 trial data - Investing.com
Soligenix announces recent accomplishments and year end 2025 financial results - marketscreener.com
Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results - TradingView
Retail Trends: What analysts say about Soligenix Inc stockGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Aug Sectors: Is Soligenix Inc a strong candidate for buy and holdMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Soligenix, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Guidance Update: Will Soligenix Inc benefit from rising consumer demand2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment By Investing.com - Investing.com South Africa
Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease - NewMediaWire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease - Benzinga
Soligenix (SNGX) Gains EU Orphan Drug Designation for Dusquetide in Behcet's Disease - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment - Investing.com
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - Lelezard
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behcet's Disease - Bitget
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - NewMediaWire
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):